Recro Pharma raises close to $37M in stock offering
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
Recro Pharma Inc. closed a public offering of 6,670,000 shares at $6 apiece to raise $36.9 million in net proceeds.
The funds will help Recro advance development of injectable meloxicam to treat moderate to severe postoperative pain.
Piper Jaffray & Co. was the sole book-running manager of the issue, with Janney Montgomery Scott and ROTH Capital Partners acting as co-managers.
